Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein. Jiao F, Andrianov AM, Wang L, Furs KV, et al. J Med Virol 2023;95:e29145.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jiao F, Andrianov AM, Wang L, Furs KV, et al. Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein. J Med Virol 2023;95:e29145.
PMID: 37804480